C&G Editor in Chief, Erin Harris

  1. BlueRock Advances Cell Therapy For Parkinson's Disease 9/30/2025

    BlueRock Therapeutics has advanced its allogeneic stem cell-derived therapy bemdaneprocel into the pivotal Phase III trial for Parkinson’s disease, aiming to restore regulated dopamine signaling, improve quality of life, and potentially transform the treatment paradigm.

  2. Driving Prostate Cancer Innovation Through Immunotherapy With OS Therapies' Dr. Robert Petit 9/26/2025

    OS Therapies' Dr. Robert Petit discusses the evolving role of immunotherapy in prostate cancer.

  3. The Future of Cancer Immunotherapy Through Allogeneic NK Cell Innovation 9/26/2025

    Our recent Cell & Gene Live, Building The Future Of Cancer Immunotherapy Through Allogeneic NK Cell Innovation, featuring expert panelists NKILT Therapeutics' Raphaël Ognar and NKore BioTherapeutics' Tracy Ryan covered the state of NK cell science, persistence challenges, safety, scalability, and the unique engineering breakthroughs shaping the future of oncology care.

  4. Precigen Secures FDA Approval For PAPZIMEOS And Redefines RRP Treatment 8/27/2025

    Precigen has received FDA approval for PAPZIMEOS, the first therapy for recurrent respiratory papillomatosis, marking a major advance in patient care.

  5. Navigating Regulatory Complexity In Cell And Gene Therapy 8/26/2025

    This is a recap of the first three episodes of FDA Fridays, a special four-week series from Cell & Gene: The Podcast. These conversations shed light on the current challenges, best practices, and forward-looking strategies shaping the CGT regulatory environment.

  6. Accelerating NAMs For A Human-Based Future In CGT Development 8/1/2025

    The Complement-ARIE Consortium, led by FNIH’s Stacey Adam, Ph.D., is advancing the development, validation, and regulatory adoption of human-based new approach methodologies (NAMs) to transform preclinical testing and accelerate cell and gene therapy development.

  7. Navigating The Complexities Of NK Cell Therapy Development 7/30/2025

    Deloitte's Amit Agarwal and Ashraf Husain share expert insights on how NK cell therapy developers can overcome manufacturing, supply chain, and commercialization challenges to successfully scale these promising therapies.

  8. Redefining CGT With Exosomes And EVs 7/16/2025

    July’s Cell & Gene Live featured a comprehensive look at the scientific advances, clinical promise, manufacturing hurdles, and regulatory considerations shaping extracellular vesicle and exosome-based therapies. 

  9. Inside AviadoBio And Astellas's Shared Mission To Bring Gene Therapy To Patients With FTD-GRN 7/2/2025

    AviadoBio and Astellas have joined forces to advance an investigational gene therapy designed to treat frontotemporal dementia with progranulin mutations (FTD-GRN), aiming to address a critical unmet need in neurodegenerative disease.

  10. Advancing Gene Delivery: LNPs, Adenovirus, Lentivirus, And More 6/24/2025

    During this month’s Cell and Gene Live, Advancing Gene Delivery: LNPs, Adenovirus, Lentivirus, And More, expert panelists Francesca Barone, M.D., Ph.D., CSO at Candel Therapeutics and Karen Kozarsky, Ph.D., President of Vector BioPartners shared their perspectives on current challenges, technological innovations, and future directions in gene therapy vector development and application.